Medical Developments share price halted amid 'significant near-term opportunities'

The company seeks to raise additional capital.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medical Developments shares are on ice today 
  • The company seeks to raise $30 million to fund growth initiatives 
  • The Medical Developments share price is down more than 42% this year to date 

The Medical Developments International Ltd (ASX: MVP) share price is on ice today following a company requested trading halt.

The ASX granted the trading pause before market open. Prior to being put into the trading halt, the last bid for the Medical Developments share price was $2.40 apiece.

Woman holding out her hand, symbolising a trading halt.

Image source: Getty Images

What was announced?

Medical Developments advised that it will complete a fully underwritten capital raising of $30 million.

This will be comprised of a $15 million placement and a $15 million pro rata accelerated non-renounceable entitlement offer.

It hopes to achieve a cash balance of $49 million post offer to fund three core areas. Per the announcement:

Post transaction MVP's cash balance will be A$49m which will fund:

– continuing execution of the Company's direct sales strategy in the large European
market

– expansion of the Australian business into the emergency sector and further growth in
the ambulance sector

– further investment in business capability to enable global growth

The 1 for 9.5 pro-rata accelerated non-renounceable entitlement offer seeks to raise $15 million. It comes with 1 attaching option to acquire 1 fully paid ordinary share for every 2.5 new shares
issued.

Whereas the placement is targeted towards sophisticated investors with 1 option for every 2.5 new shares issued.

Speaking on the announcement, chairman Gordon Naylor said the company was "pleased with [its] strong revenue growth in FY22and expect this to continue into FY23".

"With a strong funding position following the capital raising, we look forward to investing to continue to deliver on our growth strategy."

The Medical Developments share price is down more than 42% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 28% in a year, should I buy the dip on Resmed shares right now?

A leading analyst provides his outlook for the beaten-down ResMed share price.

Read more »

A businessman points to an arrow going up on a graph, indicating a share price rise for an ASX company.
Broker Notes

Up 1,277% in a year, why 4DMedical shares are tipped for more outsized gains

A leading analyst forecasts more outperformance from 4DMedical’s rocketing shares. But why?

Read more »

A person bounces another up high from a seesaw as the one in the air looks through a telescope into the future.
Healthcare Shares

Has the CSL share price finally bottomed out?

Is this beaten-down ASX healthcare giant finally turning a corner?

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Why everyone selling Cochlear shares right now could regret it in 3 years

Cochlear shares are down 65%. Here's why investors selling up right now could look back and wish they'd done the…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Healthcare Shares

Here's what brokers tip for CSL shares over the next 12 months

The beaten-down biotech company's shares are still falling.

Read more »

three excited doctors with hands in the air
Healthcare Shares

Pro Medicus announces $16m US contract renewal

Pro Medicus secures a major US contract renewal, strengthening its US footprint and underlining continued client retention.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

How much higher could Pro Medicus shares go? 2 brokers weigh in

New contract wins and a positive take on AI are tailwinds for this company.

Read more »

A bored man sits at his desk, flat after seeing the latest news on the share market.
Healthcare Shares

Why did CSL shares crash 22% in May?

Things went from bad to worse for this fallen giant last month.

Read more »